📊 PLSH Key Takeaways
Is Panacea Life Sciences Holdings, Inc.. (PLSH) a Good Investment?
Panacea Life Sciences is in severe financial distress with negative stockholders equity of -$9.6M, indicating technical insolvency. The company is burning cash with -$357.1K operating cash flow, maintains only $107.6K in cash reserves, and has critically low liquidity ratios (0.23x current ratio). While gross margins of 63.1% suggest viable product economics, the company cannot sustain operations at its current trajectory.
Why Buy Panacea Life Sciences Holdings, Inc.. Stock? PLSH Key Strengths
- Decent gross margin of 63.1% indicates reasonable product pricing and cost structure
- Net loss improved 12.3% YoY showing trajectory toward reduced losses
- Operating in medicinal chemicals sector with established market demand
PLSH Stock Risks: Panacea Life Sciences Holdings, Inc.. Investment Risks
- Negative stockholders equity of -$9.6M reflects technical insolvency from balance sheet perspective
- Critical cash shortage with only $107.6K on hand insufficient for continued operations
- Negative operating cash flow of -$357.1K indicates company is burning cash every period
- Severe liquidity crisis: current ratio of 0.23x and quick ratio of 0.03x preclude debt service
- Minimal revenue base of $1.1M with only 3.7% YoY growth insufficient to achieve profitability
- Data freshness issue: latest available data from March 31, 2024 (nearly 2 years old)
Key Metrics to Watch
- Cash balance and runway to insolvency
- Operating cash flow trajectory and path to profitability
- Revenue growth acceleration and operating leverage
- Stockholders equity recovery and balance sheet stabilization
Panacea Life Sciences Holdings, Inc.. (PLSH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
PLSH Profit Margin, ROE & Profitability Analysis
PLSH vs Materials Sector: How Panacea Life Sciences Holdings, Inc.. Compares
How Panacea Life Sciences Holdings, Inc.. compares to Materials sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Panacea Life Sciences Holdings, Inc.. Stock Overvalued? PLSH Valuation Analysis 2026
Based on fundamental analysis, Panacea Life Sciences Holdings, Inc.. has mixed fundamental signals relative to the Materials sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Panacea Life Sciences Holdings, Inc.. Balance Sheet: PLSH Debt, Cash & Liquidity
PLSH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Panacea Life Sciences Holdings, Inc..'s revenue has grown significantly by 16% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.62 indicates the company is currently unprofitable.
PLSH Revenue Growth, EPS Growth & YoY Performance
PLSH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2024 | $677.5K | -$1.4M | $-0.09 |
| Q3 2023 | $347.9K | -$2.2M | $-0.13 |
| Q2 2023 | $399.1K | -$1.9M | $-0.11 |
| Q1 2023 | $466.5K | -$1.8M | N/A |
| Q3 2022 | $366.2K | -$2.7M | N/A |
| Q2 2022 | $313.5K | $27.2K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Panacea Life Sciences Holdings, Inc.. Dividends, Buybacks & Capital Allocation
PLSH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Panacea Life Sciences Holdings, Inc.. (CIK: 0001552189)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PLSH
What is the AI rating for PLSH?
Panacea Life Sciences Holdings, Inc.. (PLSH) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PLSH's key strengths?
Claude: Decent gross margin of 63.1% indicates reasonable product pricing and cost structure. Net loss improved 12.3% YoY showing trajectory toward reduced losses.
What are the risks of investing in PLSH?
Claude: Negative stockholders equity of -$9.6M reflects technical insolvency from balance sheet perspective. Critical cash shortage with only $107.6K on hand insufficient for continued operations.
What is PLSH's revenue and growth?
Panacea Life Sciences Holdings, Inc.. reported revenue of $1.1M.
Does PLSH pay dividends?
Panacea Life Sciences Holdings, Inc.. does not currently pay dividends.
Where can I find PLSH SEC filings?
Official SEC filings for Panacea Life Sciences Holdings, Inc.. (CIK: 0001552189) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PLSH's EPS?
Panacea Life Sciences Holdings, Inc.. has a diluted EPS of $-0.09.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PLSH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Panacea Life Sciences Holdings, Inc.. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PLSH stock overvalued or undervalued?
Valuation metrics for PLSH: ROE of N/A (sector avg: 14%), net margin of -136.9% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy PLSH stock in 2026?
Our dual AI analysis gives Panacea Life Sciences Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PLSH's free cash flow?
Panacea Life Sciences Holdings, Inc..'s operating cash flow is $-357.1K, with capital expenditures of $5.0K. FCF margin is -34.3%.
How does PLSH compare to other Materials stocks?
Vs Materials sector averages: Net margin -136.9% (avg: 10%), ROE N/A (avg: 14%), current ratio 0.23 (avg: 1.6).